tradingkey.logo
tradingkey.logo
Search

ImmuCell Corp

ICCC
Add to Watchlist
10.290USD
-0.710-6.45%
Close 07/02, 13:00ETQuotes delayed by 15 min
93.09MMarket Cap
LossP/E TTM

ImmuCell Corp

10.290
-0.710-6.45%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

-6.45%

5 Days

+5.11%

1 Month

+6.41%

6 Months

+73.82%

Year to Date

+67.32%

1 Year

+55.44%

Key Figures
10.930Open
10.930High
41.07KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.45%Turnover Ratio
11.000Prev. Close
10.070Low
289.75KTurnover
LossP/E Static
3.20P/B
0.00%Div Yield TTM
-1.22%ROA
10.75052wk High
2.02Volume Ratio
-2.16MNet Profit
9.05MShares
-0.0617EPS TTM
0.54Beta
-1.88%ROE
4.52052wk Low
7.82%Amplitude
44.97%Gross Margin
93.09MMarket Cap
3.17Reward/Risk
2.98%Risk Rate

TradingKey Stock Score of ImmuCell Corp

Currency: USD Updated: 2026-07-01

Key Insights

ImmuCell Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 102 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ImmuCell Corp's Score

Industry at a Glance

Industry Ranking
102 / 157
Overall Ranking
303 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

ImmuCell Corp Highlights

StrengthsRisks
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.64M.
Undervalued
The company’s latest PE is -178.28, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.16M shares, increasing 9.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space

ImmuCell Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ImmuCell Corp Info

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Ticker SymbolICCC
CompanyImmuCell Corp
CEOte Boekhorst (Olivier)
Websitehttps://immucell.com/

FAQs

What is the current price of ImmuCell Corp (ICCC)?

The current price of ImmuCell Corp (ICCC) is 11.00.

What is the symbol of ImmuCell Corp?

The ticker symbol of ImmuCell Corp is ICCC.

What is the 52-week high of ImmuCell Corp?

The 52-week high of ImmuCell Corp is 10.75.

What is the 52-week low of ImmuCell Corp?

The 52-week low of ImmuCell Corp is 4.52.

What is the market capitalization of ImmuCell Corp?

The market capitalization of ImmuCell Corp is 99.51M.

What is the Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC)?

The Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC) is -0.12.